Literature DB >> 3046164

Structure, function, and intracellular processing of paramyxovirus membrane proteins.

T G Morrison1.   

Abstract

Paramyxoviruses are a fascinating group of viruses with diverse hosts and disease manifestations. They are valuable systems for studying viral pathogenesis, molecular mechanisms of negative strand viral replication, and glycoprotein structure and function. In the past few years this group of viruses has received increased attention and as a result there is a wealth of new information. For example, most of the genes of many paramyxoviruses have been cloned and sequenced. The recent availability of sequence information from a number of paramyxoviruses now allows the direct comparison of the amino acid sequence and determinants of secondary structure of analogous genes across the family of viruses. Such comparisons are revealing for two reasons. First, results provide clues to the evolution of these viruses. Second, and more importantly, comparisons of analogous genes may point to sequences and structural determinants that are central to the function of the individual proteins. Below is a comparison of five of the paramyxovirus genes with a discussion of the implications of common structural determinants for function, intracellular processing, and evolutionary origin. The focus is on the paramyxovirus membrane proteins, although other proteins are discussed briefly.

Mesh:

Substances:

Year:  1988        PMID: 3046164     DOI: 10.1016/0168-1702(88)90010-x

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  29 in total

1.  The human fibroblast receptor for gp86 of human cytomegalovirus is a phosphorylated glycoprotein.

Authors:  S Keay; B Baldwin
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

2.  Oligomeric organization of gp120 on infectious human immunodeficiency virus type 1 particles.

Authors:  C D Weiss; J A Levy; J M White
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

3.  Neutralization map of the hemagglutinin-neuraminidase glycoprotein of Newcastle disease virus: domains recognized by monoclonal antibodies that prevent receptor recognition.

Authors:  R M Iorio; R J Syddall; J P Sheehan; M A Bratt; R L Glickman; A M Riel
Journal:  J Virol       Date:  1991-09       Impact factor: 5.103

4.  Design of an engineered N-terminal HIV-1 gp41 trimer with enhanced stability and potency.

Authors:  John J Dwyer; Karen L Wilson; Kimberly Martin; Jennifer E Seedorff; Aisha Hasan; Robyn J Medinas; Donna K Davison; Michael D Feese; Hans-Thomas Richter; Hidong Kim; Thomas J Matthews; Mary K Delmedico
Journal:  Protein Sci       Date:  2008-04       Impact factor: 6.725

5.  Spike protein oligomerization control of Semliki Forest virus fusion.

Authors:  M Lobigs; J M Wahlberg; H Garoff
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

6.  A temperature-sensitive mutant of Newcastle disease virus defective in intracellular processing of fusion protein.

Authors:  H Matsumura; Y Futaesaku; S Kohno; A Sugiura; M Kohase
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

Review 7.  Immunity to human and bovine respiratory syncytial virus.

Authors:  T G Kimman; F Westenbrink
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

8.  Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus.

Authors:  Matthew I Bonaparte; Antony S Dimitrov; Katharine N Bossart; Gary Crameri; Bruce A Mungall; Kimberly A Bishop; Vidita Choudhry; Dimiter S Dimitrov; Lin-Fa Wang; Bryan T Eaton; Christopher C Broder
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-05       Impact factor: 11.205

9.  Identification of amino acids recognized by syncytium-inhibiting and neutralizing monoclonal antibodies to the human parainfluenza type 3 virus fusion protein.

Authors:  K V Coelingh; E L Tierney
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

10.  Protease-induced infectivity of hepatitis B virus for a human hepatoblastoma cell line.

Authors:  X Lu; T M Block; W H Gerlich
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.